Catalent Appoints First President of Asia Pacific Group - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Catalent Appoints First President of Asia Pacific Group



Catalent has named David Heyens in the new role of president of Catalent Asia Pacific. Reporting directly to Catalent’s president and CEO, John Chiminski, Heyens was hired to drive Catalent’s growth in the region following the company’s recent expansion into China, and build on Catalent’s regional operations in Japan, Australia, and Singapore.

Replacing Heyens as the president of Catalent Softgel Technologies will be Aris Gennadios, PhD. Also reporting to Chiminski, Gennadios will have full strategic responsibility for the soft gel development, delivery, and supply business with 10 global manufacturing facilities that deliver pharmaceutical, generic, and consumer health soft gel products to markets worldwide.

Source: Catalent

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here